BRISTOL-MYERS SQUIBB COMPANY AND MEDIVIR AB ANNOUNCE WORLDWIDE COLLABORATION TO DEVELOP AND COMMERCIALIZE MIV-170 FOR THE TREATMENT OF HIV-1 INFECTION IN ADULTS

Bristol-Myers Squibb Company and Medivir AB announced a worldwide collaboration to develop and commercialize MIV-170, a preclinical non-nucleoside reverse transcriptase inhibitor, or NNRTI, intended for the treatment of HIV-1 infection in adults as part of an antiretroviral drug regimen. BioSpace (http://www.biospace.com/news_story.aspx?StoryID=29794&full=1)